Levonorgestrel
/api/v1/drug/levonorgestrelMechanism of action
Sourced from openFDAMechanism-of-action class: Progestational Hormone Receptor Agonists.
Indications
Sourced from openFDA- Use for women to reduce chance of pregnancy after unprotected sex (if a contraceptive failed or if you did not use birth control)ICD-10: Z30.9
Dosage & administration
Sourced from openFDADirections • take as soon as possible within 72 hours (3 days) after unprotected sex. The sooner you take it the better it will work. • if you vomit within 2 hours after taking the medication, call a healthcare professional to find out if you should repeat the dose
Warnings & precautions
Sourced from openFDAAllergy alert: Do not use if you have ever had an allergic reaction to levonorgestrel Sexually transmitted diseases (STDs) alert: This product does not protect against HIV/AIDS or other STDs Do not use • if you are already pregnant (because it will not work) • for regular birth control Ask a doctor or pharmacist before use if you are taking efavirenz (HIV medication) or rifampin (tuberculosis treatment) or medication for seizures (epilepsy). These medications may reduce the effectiveness of levonorgestrel. When using this product you may have • menstrual changes • tiredness • breast pain • nausea • headache • vomiting • lower stomach (abdominal) pain • dizziness Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
Approval history
Sourced from openFDA- Dec 6, 2000NDANDA021225Bayer Hlthcare
- Sep 5, 2003NDANDA021544Teva Branded Pharm
- Nov 21, 2003NDANDA021258Bayer Hlthcare
- May 25, 2006NDANDA021840Teva Branded Pharm
- Oct 24, 2008NDANDA022262Teva Branded Pharm
- Jul 10, 2009NDANDA021998Fdn Consumer
- Jan 9, 2013NDANDA203159Bayer Hlthcare
- Mar 28, 2013NDANDA204061Teva Branded Pharm
FAERS reports
- 1Device Expulsion45,20922%
- 2Device Dislocation20,1889.8%
- 3Menstruation Irregular15,0537.3%
- 4Vaginal Haemorrhage15,0307.3%
- 5Genital Haemorrhage11,0545.4%
- 6Abdominal Pain Lower9,2594.5%
- 7Nausea8,8404.3%
- 8Abdominal Pain8,6584.2%
- 9Procedural Pain8,3674.1%
- 10Pain7,6603.7%
- 11Uterine Perforation7,4253.6%
- 12Drug Ineffective7,4223.6%
- 13Pelvic Pain6,8483.3%
- 14Headache6,7283.3%
- 15Pregnancy With Contraceptive Device5,9152.9%
Literature
Recent PubMed references pinned to Levonorgestrel as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Short fibers recruiting inflammatory exudate via smart-responsive estrogen antagonism for endometrial hyperplasia.Biomaterials · 2026 · Liu M, Zhou Y, Kang H, et al.PMID 42155173DOI 10.1016/j.biomaterials.2026.124306
- Levonorgestrel intrauterine system: do the contraceptive benefits outweigh the risks in light of new FSRH guidance?The British journal of general practice : the journal of the Royal College of General Practitioners · 2026 · Joseph APMID 42134930DOI 10.3399/bjgp26X745389
- Preliminary Evaluation of Leuprorelin Acetate Microspheres Plus Levonorgestrel-Releasing Intrauterine System in Endometriosis: An Exploratory Study Focusing on BNIP3 and EPAC1 Expression.The journal of obstetrics and gynaecology research · 2026 · Liu J, Li M, Zhang J, et al.PMID 42120175DOI 10.1111/jog.70304
- Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.Journal of clinical pharmacology · 2026 · Cronenberger C, Amin NB, Le VH, et al.PMID 42053447DOI 10.1002/jcph.70158
- Life-time levonorgestrel exposure causes intergenerational alterations of the thyroid-catecholaminergic-GABAergic functional network in zebrafish (Danio rerio).Environmental research · 2026 · Hu X, Cai Q, Wu J, et al.PMID 42031046DOI 10.1016/j.envres.2026.124496
- Differences in Physiologically Based Pharmacokinetic Predictions between Software Platforms Can Be Clinically Relevant: Cases of Levornestrogel and Ethinylestradiol Concentrations with SIMCYP versus PK-Sim from a User Perspective.European journal of drug metabolism and pharmacokinetics · 2026 · Massaux C, Dogné JM, Musuamba FT, et al.PMID 41934490DOI 10.1007/s13318-026-00988-1
- Differential regulation of endometrial receptivity markers by levonorgestrel-releasing and copper intrauterine devices: A cross-sectional study.Journal of gynecology obstetrics and human reproduction · 2026 · Karakelleoğlu GPMID 41921785DOI 10.1016/j.jogoh.2026.103171
- Association of Levonorgestrel-Containing Emergency Contraceptive Pills with Breast Cancer in Premenopausal Latin American Women: The PRECAMA Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026 · Cabrera-López M, Ángeles-Llerenas A, de la Vara-Salazar E, et al.PMID 41879672DOI 10.1158/1055-9965.EPI-25-1235
Clinical trials
The 10 most recently updated of 486 ClinicalTrials.gov registrations naming Levonorgestrel as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial CancerNot yet recruiting · Phase 4 · Interventional · 80 enrolled · Hospital Universitari de BellvitgeNCT07462663updated 2026-06-10
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaRecruiting · Phase 2 · Interventional · 20 enrolled · University of FloridaNCT07107334updated 2026-06-08
- Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)Recruiting · Phase 1 · Interventional · 24 enrolled · Deciphera Pharmaceuticals, LLCNCT07539090updated 2026-06-05
- Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical HyperplasiaRecruiting · Phase 2 · Phase 3 · Interventional · 172 enrolled · Xiaojun ChenNCT05316493updated 2026-06-04
- Effects of Copper Versus Levonorgestrel Intrauterine Devices on Mucosal Microbiota and Barrier Function Among Young African WomenNot yet recruiting · Interventional · 120 enrolled · Seattle Children's HospitalNCT07627958updated 2026-06-04
- Subdermal Implant-bioabsorbable Gestrinone Pellet for Endometriosis Pelvic Pain TreatmentCompleted · Phase 2 · Interventional · 100 enrolled · Science Valley Research InstituteNCT05570786updated 2026-06-03
- Michigan Contraceptive Access, Research, and Evaluation Study Children: Phase 1Recruiting · Interventional · 4,700 enrolled · University of MichiganNCT04371900updated 2026-06-02
- Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs PlaceboRecruiting · Phase 4 · Interventional · 790 enrolled · Lori GawronNCT06162611updated 2026-06-02
- Michigan Contraceptive Access, Research, and Evaluation Study: Phase 1Active not recruiting · Interventional · 4,633 enrolled · University of MichiganNCT03673007updated 2026-06-02
- Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 MonthsRecruiting · Phase 3 · Interventional · 207 enrolled · BayerNCT06904274updated 2026-05-27
Frequently asked questions
- How does Levonorgestrel work?
- Mechanism-of-action class: Progestational Hormone Receptor Agonists.
- What is Levonorgestrel used for?
- According to FDA labeling, Levonorgestrel carries indications including: Use for women to reduce chance of pregnancy after unprotected sex (if a contraceptive failed or if you did not use birth control). This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
- What class of drug is Levonorgestrel?
- Levonorgestrel is classified as Emergency contraceptives, Progestogens, Progestin, Progestin-containing Intrauterine System, Progestational Hormone Receptor Agonists, Decreased Embryonic Implantation, Hypothalamic Endocrine Activity Alteration, Increased Blood Pressure, Inhibit Ovulation, Inhibit Ovum Fertilization.
- What are the brand names for Levonorgestrel?
- Levonorgestrel is marketed under brand names including After banger, AfterPlan, Aftera, Afterpill, Climara Pro, Curae, E-Con, EContra.
levonorgestrel is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.